The text starts here.

News Release

August 20, 2002

Eisai Launches JUVELUX(R)L
For Relief of Hot and Cold Flashes Associated with Menopause

Eisai Co., Ltd. (Headquarters: Tokyo, President: Haruo Naito), launches on August 21 Juvelux(R)L, a combination of natural vitamin E and two herbs for alleviation of hot and cold flashes associated with menopause.
Common unpleasant symptoms of menopause such as hot and cold flashes, numbness in the hands and feet, and stiffness in the shoulders result from hormonal imbalances, and poor peripheral circulation, among others.
Juvelux(R)L relieves these symptoms with natural vitamin E and two medicinal herbs (Toki and Kojin extracts). Juvelux(R)L comes in brown soft capsules. This product is the first vitamin E based product with an active ingredient including Toki extract, therefore post-marketing surveillance studies for three years will be conducted.
Juvelux(R)L was developed to contribute to self-medication of patients experiencing menopause.

Effects of Vitamin E
* Adjusts hormonal imbalance and alleviates hot and cold flashes associated with menopause.
* Improves systemic circulation and stiffness in the shoulders and neck, numbness and coldness in the hands and feet.
* Prevents oxidation of fat, and should be supplied actively for senior citizens because lipid peroxide can easily increase.
Effects of Toki
* Warms up the body, especially improving congestion of blood in the lower abdomen, and activates circulation.
Effects of Kojin
* Adjusts hormones and relieves menopausal hot and cold flashes.

Along with the launch of Juvelux(R)L, Eisai established an Internet Website named 'Juvelanet' and will provide various information on health and beneficial daily life for people in menopause.

URL of the Juvelanet : (Japanese Only)

Eisai Co., Ltd. is a research based human healthcare company which discovers, develops and markets products in more than 30 countries. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. The company reported sales of over $3.2 billion in 2001 with approximately 13 percent of sales spent for research and development.